The European Health Technology Assessment (EU-HTA) aims to harmonise HTA across Europe, enhancing efficiency and reducing duplication of work for national authorities. This paper explores key components of the EU-HTA framework, challenges, future perspectives, and implications for pharmaceutical companies, primarily concentrating on drug evaluation over medical devices

Scientific evidence needs might differ substantially between the different stakeholders, but they also vary between countries due to different philosophies in the assessment of healthcare interventions. This requires early Global Evidence Generation planning. This paper deals with the process of developing an Evidence Generation Plan (EGP).

This paper explores the basic processes around an MCR as well as its advantages and disadvantages and provides a couple of recommendations on how an “ideal” MCR should be conducted. Trade-offs researchers should be aware of in designing an MCR will be explored.